260,000 Shares in Scholar Rock Holding Corporation $SRRK Bought by Casdin Capital LLC

Casdin Capital LLC acquired a new position in shares of Scholar Rock Holding Corporation (NASDAQ:SRRK) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 260,000 shares of the company’s stock, valued at approximately $11,453,000. Scholar Rock accounts for 0.7% of Casdin Capital LLC’s portfolio, making the stock its 23rd largest position.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. JPMorgan Chase & Co. increased its stake in Scholar Rock by 161.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 713,988 shares of the company’s stock valued at $26,589,000 after buying an additional 440,401 shares during the last quarter. Jennison Associates LLC increased its stake in Scholar Rock by 74.0% in the 4th quarter. Jennison Associates LLC now owns 2,795,188 shares of the company’s stock valued at $123,128,000 after buying an additional 1,188,676 shares during the last quarter. HighVista Strategies LLC increased its stake in Scholar Rock by 90.8% in the 3rd quarter. HighVista Strategies LLC now owns 59,573 shares of the company’s stock valued at $2,218,000 after buying an additional 28,343 shares during the last quarter. Eagle Health Investments LP increased its stake in Scholar Rock by 34.9% in the 3rd quarter. Eagle Health Investments LP now owns 363,300 shares of the company’s stock valued at $13,529,000 after buying an additional 93,900 shares during the last quarter. Finally, Granahan Investment Management LLC increased its stake in Scholar Rock by 77.1% in the 3rd quarter. Granahan Investment Management LLC now owns 129,914 shares of the company’s stock valued at $4,838,000 after buying an additional 56,539 shares during the last quarter. 91.08% of the stock is currently owned by institutional investors and hedge funds.

Scholar Rock Stock Up 3.1%

Scholar Rock stock opened at $46.95 on Thursday. The firm has a market capitalization of $5.63 billion, a PE ratio of -13.08 and a beta of 0.69. The company’s 50-day moving average is $47.67 and its 200-day moving average is $45.93. Scholar Rock Holding Corporation has a fifty-two week low of $27.07 and a fifty-two week high of $52.19. The company has a debt-to-equity ratio of 0.71, a current ratio of 8.64 and a quick ratio of 8.64.

Scholar Rock (NASDAQ:SRRK) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.01). During the same period in the prior year, the business posted ($0.67) EPS. Sell-side analysts anticipate that Scholar Rock Holding Corporation will post -3.23 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on SRRK shares. Piper Sandler lifted their price target on shares of Scholar Rock from $51.00 to $58.00 and gave the company an “overweight” rating in a research note on Wednesday, March 4th. Barclays lifted their price target on shares of Scholar Rock from $53.00 to $55.00 and gave the company an “overweight” rating in a research note on Friday, May 8th. HC Wainwright boosted their price objective on shares of Scholar Rock from $58.00 to $65.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Scholar Rock in a research note on Tuesday, April 21st. Finally, Citigroup boosted their price objective on shares of Scholar Rock from $55.00 to $58.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th. Four investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $56.00.

Insider Activity at Scholar Rock

In related news, CFO Vikas Sinha sold 10,410 shares of Scholar Rock stock in a transaction dated Thursday, April 16th. The shares were sold at an average price of $49.57, for a total transaction of $516,023.70. Following the completion of the sale, the chief financial officer owned 619,856 shares of the company’s stock, valued at approximately $30,726,261.92. The trade was a 1.65% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Keith Woods sold 10,220 shares of Scholar Rock stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of $49.57, for a total transaction of $506,605.40. Following the sale, the chief operating officer directly owned 620,055 shares of the company’s stock, valued at $30,736,126.35. The trade was a 1.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 63,491 shares of company stock worth $3,147,249. 13.30% of the stock is currently owned by corporate insiders.

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).